20
Updated ACIP Recommendations for Using Hepatitis A Vaccine for Postexposure and International Travel Management Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program Institute for Human Infections and Immunity University of Texas Medical Branch Galveston, Texas

Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

  • Upload
    jirair

  • View
    35

  • Download
    1

Embed Size (px)

DESCRIPTION

Updated ACIP Recommendations for Using Hepatitis A Vaccine for Postexposure and International Travel Management. Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program Institute for Human Infections and Immunity University of Texas Medical Branch Galveston, Texas. - PowerPoint PPT Presentation

Citation preview

Page 1: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Updated ACIP Recommendations forUsing Hepatitis A Vaccine for

Postexposure and International Travel Management

Miriam J. Alter, Ph.D., MPHInfectious Disease Epidemiology Program

Institute for Human Infections and ImmunityUniversity of Texas Medical Branch

Galveston, Texas

Page 2: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

ACIP Recommendations for Pre-Exposure Use of Hepatitis A Vaccine

All children 12-23 months old Catch-up vaccination of older children in areas with

existing programs Persons at increased risk

– Travelers– Persons with chronic liver disease– Men who have sex with men– Illicit drug users

Page 3: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Hepatitis A Postexposure ProphylaxisPrevious ACIP Recommendation

A single dose of immune globulin as soon as possible [within 2 weeks of exposure]– If hepatitis A vaccine also is recommended, can

be administered simultaneously with IG Need results of a clinical trial comparing

vaccine and IG to determine if hepatitis A vaccine can be used without IG

Page 4: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Hepatitis A Vaccine Postexposure TrialItaly, 1997

Enrolled 212 household contacts (aged 1-40 years) of hospitalized hepatitis A cases– Randomized to receive vaccine (GSK) within 8 days of symptom onset of

index case, or no intervention– Outcome – IgM positive as measured at day 14 or 45 post-vaccination

Vaccine efficacy 79% (95% CI 7-95%) Trial stopped when reached statistical significance Outcomes

– 2 in vaccinated group, ages 10 and 11 years, asymptomatic with normal ALT’s

– 12 in no intervention group, aged 3-23 years, majority symptomatic with elevated ALT’s

Source: Sagliocca et al, Lancet, 1999

Page 5: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Randomized Clinical Noninferiority Hepatitis AVaccine Postexposure Trial – Almaty, Kazakhstan

Enrolled 4,524 household or daycare contacts (2-40 yrs old)– Exposed to index case within 2 weeks after index case symptom onset– No history of hepatitis A or receipt of hepatitis A vaccine or IG (within

past 6 months), chronic liver disease, or contraindications to vaccine or IG

1:1 randomization within households or daycare center classrooms to receive vaccine (VAQTA) or IG within 2 weeks after index case symptom onset

Primary outcome – clinical hepatitis A– Positive for IgM anti-HAV– A serum ALT level at least 2x the upper limit of normal– Symptoms consistent with viral hepatitis

Source: Victor JC et al. NEJM 2007;357:1685-94.

Page 6: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Clinical endpoints Vaccine (n=740) IG (n=674) RR (95% CI UB)

Primary endpoint 26/740 (3.5%) 18/674 (2.7%) 1.32 (2.30)

2 to 18 years 21/628 (3.3%) 13/535 (2.4%) 1.38 (2.65)

19 to 40 years 5/112 (4.5%) 5/139 (3.6%) 1.24 (4.33)

All suspected cases 35/740 (4.7%) 27/674 (4.0%) 1.18 (1.87 )

2 to 18 years 28/628 (4.5%) 7/112 (6.3%) 1.19 (2.03)

19 to 40 years 20/535 (3.7%) 7/139 (5.0%) 1.24 (3.47)

Risks of Developing Hepatitis A Among Vaccine and IG Recipients by Age (ITTS): Children v. Adults

Page 7: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Randomized Clinical Noninferiority TrialSummary of Findings

Hepatitis A vaccine efficacy was similar to that of IG (noninferiority criteria was met)– Assuming 90% IG efficacy, point estimate of vaccine

efficacy is 86%; 95% CI upper bound is 76%– Assuming 85% IG efficacy, point estimate of vaccine

efficacy is 80%; 95% CI upper bound is 64% Risk of hepatitis A among vaccine recipients was

never >1.5% greater than among IG recipients Evidence that IG might attenuate clinical illness

Page 8: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Implications of Postexposure Study Findings:Children and Adults

Children aged 2—18 years– Data support vaccine equivalency to IG

Adults aged 19—40 years– Wider confidence intervals around point estimates of relative risk

• Small sample size in this age category

– No significant difference in crude estimate of average ALT levels– Data supported vaccine equivalency to IG

For healthy persons age ≥ 12 months – 40 years, hepatitis A vaccine at the age appropriate dose is preferred to IG because of vaccine’s advantages, including long term protection and ease of administration.

Page 9: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Other Issues for Consideration

Time since exposure– Previous study cut off at 7 days postexposure

• Results of current study largely removes theoretical concern about diminished vaccine efficacy with longer time since exposure

– No difference between groups in time since exposure– Most interventions given fairly late in 2 week postexposure

window Comparability of two US licensed vaccines

– Considered equivalent for pre-exposure use– Few head-to-head comparisons– Percent seroconversion after one dose appears similar

Page 10: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Populations not Studied in Clinical Trials:Older Adults

No data about vaccine performance postexposure in this age group

Risk of severe hepatitis A increases with increasing age

For persons > 40 years, IG is preferred because of the absence of information regarding vaccine performance and the more severe manifestations of hepatitis A in this age group. – Vaccine can be used if IG cannot be obtained.

Page 11: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Populations not Studied in Clinical Trials:Patients with Chronic Liver Disease and Other

Medical Conditions

Chronic liver disease and other chronic medical conditions– Known to have poorer response to vaccine

preexposure– Chronic liver disease patients have more severe

disease outcomes

Page 12: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Response to One Dose of Hepatitis A Vaccines in Selected Populations

Study Population # Studies % positive (4 wks)HIV infected 3 10%-78%

Chronic liver disease 3 63%-93%

Liver or KidneyTransplantation 3 0%-41%

Comment

Higher with higher CD4 cell count

Lower than controls; lowest in decompensatedcirrhotics

Page 13: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Hepatitis A Vaccine or Immune GlobulinPostexposure Summary

Vaccine offers a number of advantages over IG– Flexibility to use vaccine in some circumstances would be beneficial

Available data suggest vaccine is efficacious postexposure, but not all populations were studied

Suboptimal response to vaccine among patients with CLD or other chronic medical conditions

Additional data not likely to be forthcoming Need to balance practical public health implementation

considerations against limitations of available information

Page 14: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Common Settings for Postexposure Prophylaxis Status

Household and other close personal contact Child care centers

– Outbreaks now unusual Exposure to infected foodhandler

– 3-7% of reported cases are foodhandlers– ~5% worked while infectious and posed

transmission risk*– Average ~350 IG doses per episode*

• Broad range – several thousand doses not uncommon

*Source: Fiore CID 2004

Page 15: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Hepatitis A Vaccine PostexposureRationale

Benefits of vaccine– Long term protection– Ease of administration– Acceptability– Availability

Single US manufacturer of IG Cost similar to IG Brings U.S. practice in line with many other

countries that provide postexposure prophylaxis

Page 16: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Updated Recommendations for Postexposure Management of Hepatitis A

For persons age ≥12 months – 40 years, vaccine at age appropriate dose is preferred for healthy

For persons >40 years, IG is preferred because of the absence of information regarding vaccine performance and the more severe manifestations of hepatitis A in this age group. – Vaccine can be used if IG cannot be obtained.

IG should be used for children age <12 months, immunocompromised persons, persons who have been diagnosed with chronic liver disease, and persons for whom vaccine is contraindicated.

Page 17: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Updated Recommendations for Postexposure Management of Hepatitis A

Persons administered IG for whom hepatitis A vaccine is also recommended should receive a dose of vaccine simultaneously with IG.

For persons who receive vaccine, the second dose should be administered according to the licensed schedule to complete the series.

The efficacy of IG or vaccine when administered > 2 weeks after exposure has not been established.

Page 18: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Previous ACIP Recommendations for Preexposure Protection Against Hepatitis A in Travelers

Vaccine only– Travelers departing >4 weeks

Vaccine (IG may be given for optimal protection)– Travelers departing <4 weeks

IG only– Aged <12 months– Allergic to vaccine component– Elect not to receive vaccine

Page 19: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Rationale for Revisions of Hepatitis A VaccineRecommendations for At-risk Travelers

Limited data showing equivalent postexposure efficacy of IG and vaccine among healthy persons aged <40 years relevant to preexposure vaccine use among at-risk travelers

Vaccine administered anytime prior to departure should adequately protect most travelers– May not be generalizable to all populations

Page 20: Miriam J. Alter, Ph.D., MPH Infectious Disease Epidemiology Program

Revised ACIP Recommendations for Preexposure Protection Against Hepatitis A in Travelers

The first dose of hepatitis A vaccine should be administered as soon as travel is considered.– For persons 12 mo-40 yrs old, vaccine should be effective

given any time before travel– For persons >40 yrs old, immunocompromised persons, and

persons with chronic liver disease or other chronic medical conditions, also give IG if 1st vaccine dose given <2 weeks before departure

Completion of the vaccine series according to the licensed schedule is necessary for long-term protection.